Neuroscience and Opthalmics

The Novartis Neuroscience portfolio includes treatments for central nervous system disorders as well as ophthalmic conditions.
For central nervous system disorders our products cover the following disease areas:

• Alzheimer's disease
• Parkinson's disease
• Epilepsy
• Depression
• Attention-deficit hyperactivity disorder (ADHD)
• Schizophrenia

Novartis also has treatments for ophthalmic conditions, most importantly "wet" age-related macular degeneration (AMD), a leading cause of blindness in people over age 50.

Neuroscience products
Our neuroscience medicines include:*

• Exelon and Exelon Patch (rivastigmine tartrate) for the treatment of Alzheimer's disease and dementia associated with Parkinson's disease
• Trileptal (oxcarbazepine) for the treatment of epilepsy
• Stalevo (carbidopa, levodopa and entacapone) for the treatment of Parkinson's disease
• Extavia, a multiple sclerosis treatment

Ophthalmics products
In ophthalmics, Lucentis (ranibizumab) is a therapy which improves vision in patients with "wet" AMD.*

Neuroscience and ophthalmics development compounds
Novartis has a number of compounds in late-stage development, including therapies for multiple sclerosis, diabetic macular edema and depression.

 

*Not all indications are available in all countries.